LENSAR, Inc. (LNSR)
Market Cap | 84.56M |
Revenue (ttm) | 48.87M |
Net Income (ttm) | -16.63M |
Shares Out | 11.61M |
EPS (ttm) | -1.46 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 43,341 |
Open | 7.35 |
Previous Close | 7.47 |
Day's Range | 7.23 - 7.70 |
52-Week Range | 2.10 - 7.96 |
Beta | 0.59 |
Analysts | n/a |
Price Target | n/a |
Earnings Date | Nov 7, 2024 |
About LNSR
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company also offers ALLY Adaptive Cataract Treatment System, a ... [Read more]
Financial Performance
In 2023, LENSAR's revenue was $42.16 million, an increase of 19.25% compared to the previous year's $35.36 million. Losses were -$14.38 million, -27.77% less than in 2022.
Financial StatementsNews
LENSAR, Inc. (LNSR) Q3 2024 Earnings Call Transcript
LENSAR, Inc. (NASDAQ:LNSR) Q3 2024 Earnings Conference Call November 7, 2024 8:30 AM ET Company Participants Cameron Radinovic - Investor Relations, Burns McClellan Nicholas Curtis - Chief Executive ...
LENSAR Reports Third Quarter 2024 Results and Provides Business Update
24 ALLY Robotic Laser Cataract Systems™ placed in 3Q 2024 including 11 sales in EU and Southeast Asia; Robust backlog with 24 systems pending installation as of September 30, 2024
LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ORLANDO, Fla., Nov. 01, 2024 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”) today announced that a majority of the independent members of LENSAR's board of directors grant...
LENSAR to Report Third Quarter 2024 Financial Results on Thursday, November 7, 2024
ORLANDO, Fla., Oct. 31, 2024 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced robotic laser solutions for the treatm...
One Millionth Procedure Completed Using LENSAR's Cataract Laser Systems
ORLANDO, Fla., Oct. 08, 2024 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced robotic laser solutions for the treatm...
LENSAR to Participate in Two Upcoming Investor Conferences
ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR®, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced laser solutions for the treatment of cataracts, today ...
LENSAR, Inc. (LNSR) Q2 2024 Earnings Call Transcript
LENSAR, Inc. (NASDAQ:LNSR) Q2 2024 Earnings Conference Call August 8, 2024 8:30 AM ET Company Participants Cameron Radinovic - IR Nicholas Curtis - CEO & Director Thomas Staab - CFO Conference Call P...
LENSAR Reports Second Quarter 2024 Results and Provides Business Update
ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR®, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced laser solutions for the treatment of cataracts, today ...
LENSAR Announces Certification for the ALLY® Adaptive Cataract Treatment System in the European Union
ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced laser solutions for the treatment of cataracts, today a...
LENSAR to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024
ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced laser solutions for the treatment of cataracts, today a...
LENSAR to Participate in the 2024 Leerink Partners Healthcare Crossroads Conference
ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser solutions for the treatment of catara...
LENSAR, Inc. (LNSR) Q1 2024 Earnings Call Transcript
LENSAR, Inc. (NASDAQ:LNSR) Q1 2024 Earnings Conference Call May 9, 2024 8:30 AM ET Company Participants Lee Roth - Burns McClellan Nicholas Curtis - CEO Thomas Staab - CFO Conference Call Participant...
LENSAR Reports First Quarter 2024 Results and Provides Business Update
ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser solutions for the treatment of catara...
LENSAR to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024
ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser solutions for the treatment of catara...
LENSAR, Inc. (LNSR) Q4 2023 Earnings Call Transcript
LENSAR, Inc. (NASDAQ:LNSR) Q4 2023 Earnings Conference Call March 4, 2024 8:30 AM ET Company Participants Cameron Radinovic - Burns McClellan Nicholas Curtis - Chief Executive Officer Thomas Staab - ...
LENSAR Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced femtosecond laser solutions for the treatment of catara...
LENSAR to Report Fourth Quarter and Full Year 2023 Financial Results on Monday, March 4, 2024
ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser solutions for the treatment of catara...
LENSAR, Inc. (LNSR) Q3 2023 Earnings Call Transcript
LENSAR, Inc. (NASDAQ:LNSR) Q3 2023 Earnings Conference Call November 9, 2023 8:30 AM ET Company Participants Cameron Radinovic - Burns McClellan Nicholas Curtis - CEO Thomas Staab - CFO Conference Ca...
LENSAR Reports Third Quarter 2023 Results and Provides Business Update
ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser solutions for the treatment of catara...
LENSAR to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023
ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser solutions for the treatment of catara...
LENSAR, Inc. (LNSR) Q2 2023 Earnings Call Transcript
LENSAR, Inc. (NASDAQ:LNSR) Q2 2023 Earnings Conference Call August 9, 2023 8:30 AM ET Company Participants Cameron Radinovic – Burns McClellan Nick Curtis – Chief Executive Officer Tom Staab – Chief ...
LENSAR Reports Second Quarter 2023 Results and Provides Business Update
ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser solutions for the treatment of catara...
LENSAR to Report Second Quarter 2023 Financial Results on Wednesday, August 9, 2023
ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment ...
LENSAR® Reports Adoption of ALLY® System in Multi-Center Ophthalmology Groups
ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment ...
LENSAR, Inc. (LNSR) Q1 2023 Earnings Call Transcript
LENSAR, Inc. (NASDAQ:LNSR) Q1 2023 Earnings Conference Call May 15, 2023 8:30 AM ET Company Participants Lee Roth - Burns McClellan Nicholas Curtis - Chief Executive Officer Thomas Staab - Chief Fina...